Interestingly, decreased fasting FGF-19 levels, reflecting impaired intestinal or hepatic FXR signalling, have also been associated with obesity and the development of metabolic-associated fatty liver disease (MAFLD) [30,31]. The gene discussed is FGF19; the disease is Obesity.